Cargando…

Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors

Introduction: In the current study, we aimed to assess the impact of antibiotics (ATB) and metabolic parameters on clinical outcome of non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI). Methods: Data from fifty NSCLC patients referred for ICI between Dece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castello, Angelo, Rossi, Sabrina, Toschi, Luca, Lopci, Egesta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002619/ https://www.ncbi.nlm.nih.gov/pubmed/33803006 http://dx.doi.org/10.3390/jcm10061251

Ejemplares similares

Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters
por: Castello, Angelo, et al.
Publicado: (2020)

Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors
por: Castello, Angelo, et al.
Publicado: (2020)

Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1
por: Castello, Angelo, et al.
Publicado: (2020)

18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art
por: Castello, Angelo, et al.
Publicado: (2020)

The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria
por: Castello, Angelo, et al.
Publicado: (2022)

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [(18)F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
por: Lopci, Egesta
Publicado: (2021)

Advances in Lung Cancer Imaging and Therapy
por: Lopci, Egesta, et al.
Publicado: (2021)

Meditating on Cancer Management at the Time of Immunotherapy
por: Lopci, Egesta
Publicado: (2022)

Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come
por: Toschi, Luca, et al.
Publicado: (2017)

Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy
por: von Itzstein, Mitchell S., et al.
Publicado: (2022)

Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy
por: Linguanti, Flavia, et al.
Publicado: (2022)

Editorial: Response assessment of radioligand therapies
por: Lopci, Egesta, et al.
Publicado: (2022)

Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Murata, Daiki, et al.
Publicado: (2023)

Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Matsuo, Norikazu, et al.
Publicado: (2023)

Comparison of MRI vs. [(18)F]FDG PET/CT for Treatment Response Evaluation of Primary Breast Cancer after Neoadjuvant Chemotherapy: Literature Review and Future Perspectives
por: Caracciolo, Matteo, et al.
Publicado: (2023)

Additional value of volumetric and texture analysis on FDG PET assessment in paediatric Hodgkin lymphoma: an Italian multicentric study protocol
por: Lopci, Egesta, et al.
Publicado: (2021)

The Role of [(68)Ga]PSMA PET/CT for Clinical Suspicion of Prostate Cancer in Patients with or without Previous Negative Biopsy: A Systematic Review
por: Caracciolo, Matteo, et al.
Publicado: (2022)

Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Wang, Chengdi, et al.
Publicado: (2019)

Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors
por: Afzal, Muhammad Z, et al.
Publicado: (2019)

The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab
por: Bauckneht, Matteo, et al.
Publicado: (2021)

Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors
por: Rojas, Frank, et al.
Publicado: (2022)

Impact of the use of antibiotics on the clinical response to immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Barbosa, Cristina Martinez-Mugica, et al.
Publicado: (2022)

Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study
por: Jang, Jeong Yun, et al.
Publicado: (2021)

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
por: Mundra, Vatsala, et al.
Publicado: (2023)

Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
por: Fujita, Kohei, et al.
Publicado: (2020)

Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non‐small cell lung cancer (AB‐CLICaP)
por: Ruiz‐Patiño, Alejandro, et al.
Publicado: (2020)

The Role of Molecular Imaging in Patients with Brain Metastases: A Literature Review
por: Urso, Luca, et al.
Publicado: (2023)

Metabolism of Stem and Progenitor Cells: Proper Methods to Answer Specific Questions
por: Martano, Giuseppe, et al.
Publicado: (2019)

Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
por: Friedlaender, Alex, et al.
Publicado: (2020)

The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors
por: Takada, Kazuki, et al.
Publicado: (2022)

Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Jung, Chi Young, et al.
Publicado: (2018)

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
por: Qiu, Zhenbin, et al.
Publicado: (2019)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
por: Soh, Junichi, et al.
Publicado: (2021)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Ushio, Ryota, et al.
Publicado: (2022)

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022)

Antibiotics Associated with Lower Survival in Hepatocellular Cancer Patients Receiving Immune Checkpoint Inhibitors Independent of Tumor Status
por: Cheung, Ka Shing, et al.
Publicado: (2022)

Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors
por: Zhao, Xinmin, et al.
Publicado: (2022)

Predictive value of DOT1L mutations for clinical outcomes in non‐small‐cell lung cancer patients receiving immune checkpoint inhibitor therapy
por: Guo, Tianxing, et al.
Publicado: (2023)

Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma
por: Donadon, Matteo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_28l27drotlklu8rmoe852rll0s